Corporate Presentation April 2017
|
|
- Kristin Henderson
- 5 years ago
- Views:
Transcription
1 Corporate Presentation April 2017
2 Breakthrough technology for gynecological cancers Corporate Presentation April 2017 Michael T. Redman - CEO Oncolix
3 CAUTIONARY NOTICE REGARDING FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements. These statements relate to future events or future financial performance of the Company including among others (i) completion of our Phase I and future clinical trials (ii) anticipated trends in the Company s financial condition and results of operations, (iii) the possible and actual results of the Company s efforts to obtain and maintain various approvals from the FDA relating to its products; and (iv) the Company s business strategy for, among other things, testing, developing, producing, distributing and in the future possibly selling and/or leasing its product candidates and its other proposed products. These forward-looking statements are based on the Company s expectations as of the date of this presentation and are subject to a number of known and unknown risks and uncertainties. Actual results could differ significantly from these forward-looking statements. Oncolix
4 Investment Highlights Leadership Compelling Science Novel Target Clinical Stage Robust IP News Flow Experienced management & board public and private companies Prolanta is a first-in class therapeutic protein with blockbuster potential in gynecological cancers MD Anderson discovered the autophagy mechanism of action Phase I ovarian cancer trial underway, will be completed in Q Prolanta covered by 8 US patents, foreign patents, orphan designation, Healthcare Act Upcoming milestones include interim Phase I data, trial completion, initiation of Phase 2 Oncolix
5 Company Evolution : Company structures and advances Prolanta manufacturing Redman hired as CEO of a new company formed by GHS to focus on autologous melanoma vaccine Company named Oncolix, GHS invests $3.0 million and receives shares in exchange for IP Redman evaluates other in-house opportunities, identifying G129R (Prolanta), which had been dropped due to manufacturing costs Oncolix licenses a high-yielding E. coli expression system for G129R from Monsanto, which is expected to result in a substantial reduction in the cost of goods Oncolix terminates the autologous melanoma vaccine GHS leads $3.5 million round with manufacturer contributing $1.5 million in-kind investment : Oncolix advances $2.4 million of funding from the Texas Emerging Technology Fund Clinical protocol for Phase 1 trial in ovarian cancer submitted to FDA supported by preclinical toxicology studies and drug characterization : Recent progress: US IND granted to Oncolix to commence Phase I trial MD Anderson announces Prolanta s novel mechanism of action at the AACR meeting in Chicago Granted orphan status in the U.S. for ovarian cancer Completed $4.2 million Series A financing round in January 2015 ($14 million raised to date) Commenced Phase I dose-escalation trial for ovarian cancer Capital raise in progress up to $5+ million Oncolix
6 Leadership Michael Redman, CEO, BOD Formerly CEO of Bone Medical, CEO and founder of Opexa Pharmaceuticals; VP, Corporate Development, Aronex Pharmaceuticals; VP, Business Development, Repros Therapeutics Extensive Licensing and acquisition experience; Phase I through III clinical trial management Author of successful grant /award applications Donald Payne, Senior Vice President Formerly CFO of Sensus Drug and LifeCell Corporation; founding CEO of Nanospectra Biosciences Extensive finance, technical writing, clinical trial and audit experience Author of successful grant/award applications; co-inventor of two patents William Gannon, MD, Chief Regulatory Officer Numerous managerial experience with multinational CROs, biotech and pharmaceutical companies, primarily cancer Substantial regulatory submissions and execution of Phase I through Phase IV both US and international Anil Sood, MD, Advisor Professor & Director, Blanton-Davis Ovarian Cancer Research Program, MD Anderson Cancer Center Discovered Prolanta s mechanism of action (Autophagy) Preclinical efficacy and biomarker evaluation of Prolanta Jerry Youkey, MD, Chairman of BOD Dean, U of SC Medical School VP, Greenville Hospital System Joseph Podolski, BOD (Independent) Former CEO, Repros Therapeutics Currently have two drugs in Phase III Raised more than $200 million Dale Zajicek, BOD Former president, BioVectra Expert in manufacturing Oncolix
7 Wen Chen Inventor of Somavert and Prolanta Chen also invented G120R (Somavert ), developed by Austin, TXbased Sensus Drug Development Corp. Features same amino acid substitution but with growth hormone First clinical validation of receptor antagonism Now approved by FDA and sold by Pfizer 2016 sales: $232 million for acromegaly (chronic gigantism, an orphan indication) Wen Chen, PhD Professor Clemson University Oncolix
8 First-in-Class Prolactin Receptor Antagonist Human Prolactin: is associated with gynecological and other cancers. is involved in cell proliferation signaling. (JAK2/STAT5 and others) and angiogenesis. dimerizes with prolactin receptors for signaling. is implicated in chemotherapy resistance. has a receptor that is over-expressed on gynecological cancers. Prolanta (G129R): is a recombinant protein that is an analog of a human prolactin. has a single amino acid mutation at position 129 of prolactin, which prevents the binding and activation of the prolactin receptor. works by novel mechanisms of action autophagy but also has the potential to prevent chemoresistance in patients. is covered by eight issued US patents and more foreign patents. Prolanta has the potential to be a major breakthrough for the treatment of ovarian cancer Oncolix
9 Prolactin s Role in Cancer Receptor is over-expressed in many cancers Breast: 90% Ovarian: 80% Endometrial: 80% Elevated prolactin levels are found in gynecological and other cancers Involved in cell proliferation signaling (JAK/STAT5, Ras/Raf/MAPK and other pathways) and angiogenesis Implicated in chemotherapy resistance (GST downregulation) Autocrine/paracrine effect evident in many cancers Oncolix
10 Prolanta (G129R) Recombinant analogue of prolactin produced in E. coli. Expression system developed by Monsanto. Single amino acid substitution (arginine replaces glycine at sequence 129) to create antagonist to prolactin: Antagonist binds to only Site 1 receptor, not Site 2. Dimerization of two receptors blocked, which result in disruption of relevant signaling pathways. Packaged as lyophilized protein for subcutaneous injection. Oncolix
11 Autophagy Autophagy is broadly accepted as an avenue to pursue to treat a wide range of cancers as evidenced by recent articles in Nature, JCO, and Cancer Cell Types of programmed cell death: Apoptosis (Type I) Autophagy (Type II) Autophagy process: 1. Cell signal inducing autophagy 2. Formation of double-membrane vesicle (autophagosome) 3. Fuse with lysosome (autophagolysosome) 4. Cell death In conclusion, we now have good reasons to think that manipulation of autophagy may provide a useful way to prevent cancer development, limit tumor progression, and increase the efficacy of cancer treatments. Hippert et al, Cancer Research, 2006 The key findings from our studies are that promoting autophagic cell death through antagonism of tumor-associated prolactin can inhibit the growth and progression of human ovarian cancer. Sood et al, MD Anderson Cancer Center, submitted to Cancer Cell 2012 Oncolix
12 2016 Nobel Prize in Chemistry Dr. Yoshinori Ohsumi Father of Autophagy Recipient of the 2016 Nobel Prize for Chemistry for his work in autophagy Oncolix
13 Lead Indication: Ovarian Cancer While Prolanta may be effective in breast, prostate and gynecological cancers; ovarian cancer selected as lead indication based on the following: Clear regulatory pathway in platinum resistant ovarian cancer Unmet medical need opens up FDA accelerated approval opportunity Shorter and less expensive clinical trials Less competition for patients in this indication Potential for 1st line therapy Enhanced partnering opportunity due to higher incidence of ovarian cancer in EU Prolanta s potential as a potent drug for ovarian cancer supported by in vivo preclinical research from MD Anderson Prolanta was effective in reducing number and size of tumors. Prolanta was synergistic in combination with first line chemotherapeutics: Demonstrated synergy with chemotherapy Prolactin associated with chemo-resistance, so antagonism with Prolanta increases efficacy Dual mechanism of action in ovarian cancer: Prolanta induces autophagy in ovarian cancer cells that express a long-form of prolactin receptor (the form necessary for most intracellular signaling) Prolanta may also prevent chemoresistance by preventing GST upregulation Oncolix
14 Ovarian Cancer Statistics Incidence 2017e (US): 22,440 Deaths (US): 14,080 Diagnosed late stage: 77% 5-year survival in late stage: 28% Prevalence (US): 188,117 Prevalence (EU): 318,000 Standard of Care: Chemotherapy Oncolix
15 $1 Billion Annual Opportunity U.S. Ovarian Cancer Market Assumption: $40,000 per patient Sensitive to Chemo>6 mos. 25% 5,505 Patients - $220 Million US Incidence 22,240/Year* Resistant to Chemo <6 mos. 25% Refractory or cannot tolerate Chemo 27% 5,506 Patients - $220 Million 5,929 Patients - $237 Million Diagnosed early or unstaged 23% 5,060 Patients - $0 US Prevalence 188,000* Recurrent From prior years 10,000 Patients - $400 Million *Source: National Cancer Institute, 2017 Oncolix
16 Prolanta Opportunity as First-Line Therapy (combination with chemo) Standard of care in ovarian cancer is platinum and taxane therapy, but almost all patients develop resistance. 2 nd line chemo (Doxil, Hycamtin, Gemzar, vinorelbine, cyclophosphosphamide) response rate is 10 to 15%. Prolactin has been implicated in the process by which cancer cells become resistant to platinum and taxane therapies, as well as 2 nd line therapies. Blocking the prolactin receptor with Prolanta should enhance first-line therapy (e.g., used in combination with platinum and taxane). Chemotherapy side effects include: Renal toxicity nausea neuromotor toxicity cardiovascular events neutropenia thromobocytopenia, and anemia Prolanta may be effective as a first line therapy in combination with chemotherapy Oncolix
17 MD Anderson Ovarian Cancer Research In vivo orthotopic models of ovarian cancer: Prolanta was effective in reducing number and size of tumors. Prolanta was synergistic in combination with taxanes in reducing number and size of tumors: Literature also indicates synergy with platinum drugs. Prolactin associated with chemo-resistance, so antagonism with Prolanta increases efficacy. Mechanism of action studies in ovarian cancer: Prolanta induces autophagy in ovarian cancer cells that overexpress prolactin receptors Prolanta may prevent chemo-resistance by prolactin receptors Oncolix
18 MD Anderson Ovarian Cancer Research Prolanta as a monotherapy reduces the size and number of tumors in orthotopic ovarian cancer models (SKOV3 shown). SKOV3 Using lowest (100ug/day) dose IG10 Prolanta was synergistic with taxanes in multiple orthotopic ovarian cancer models. [Dose 100ug/day] Oncolix
19 Prolanta shows evidence of synergistic effect in breast cancer models Cummulative Tumor Volume (mm 3 ) control Herceptin G129R G129R + Herceptin ** ** ** ** * * ** ** ** * * ** ** * * * * ** Prolanta (G129R) was effective as a monotherapy in a breast cancer model, and was synergistic with Herceptin. Prolanta Alone Prolanta+Herceptin Days post inoculation Each value is a mean ± SD of 6-8 mice/group ** P < 0.01 and * P < 0.05 versus control P < 0.05 versus Herceptin alone Oncolix
20 Prolanta monotherapy or combination therapies Accumulating evidence suggests that PRL (Prolactin) opposes cytotoxicity by a wide variety of anticancer drugs. LaPensee et al, Endocrine-Related Cancer, 2010 Standard of care for ovarian cancer: 1st Line: Platinum and taxane therapy, almost all patients develop resistance 2nd line: Doxil, Hycamtin, Gemzar, vinorelbine, cyclophosphosphamide; Response rate is 10 to 15% Blocking prolactin receptors with Prolanta should enhance first-line therapy (e.g., used in combination with platinum and taxane): Blocking the effects of prolactin should enhance the apoptotic effect of platinum therapy Prolactin has been implicated in the process by which cancer cells become resistant to platinum therapy, as well as 2nd line therapies Prolanta is also synergistic with taxane therapies Oncolix
21 IND FDA has cleared Oncolix s IND for a Phase I human trial of Prolanta in recurrent and persistent ovarian cancer Manufacturing is a scalable, cgmp process with reproducibility across multiple lots Toxicity / Toxicokinetic Data Cynomolgus monkey and rabbit studies performed by Charles River Laboratories No significant adverse effects noted Oncolix
22 Global Market Potential and Risk Analysis (Ovarian Cancer Only) Assumptions: Ovarian cancer indication only Annual price of $40,000 (US, Japan, Canada) and $30,000 (Europe) Market Potential: $3 billion market $1,078 million (US) $1,710 million (W. Europe) $ 313 million (Japan) $ 95 million (Canada) Risk Analysis: Orphan status & unmet medical need: refractory & platinum resistant ovarian cancer Potential to receive regulatory approval on a well controlled Phase IIb clinical trial or smaller Phase III trials than indications such as breast cancer No direct competition - Prolanta is additive or synergistic to current therapies and no other prolactin receptor antagonists in human clinical trials in the US Lower trial costs: ovarian trials significantly less than breast cancer trials Pricing: Comparative Cost $6,000 to $10,000 per month - Avastin approved for OC in Europe Manufacturing: Prolanta IND cleared by US FDA includes the Chemistry, Manufacturing and Controls (CMC) package Drug is manufactured by an FDA-inspected facility in large commercial equipment and is one scaleup level from full commercial production Intellectual property: Eight US issued patents and additional foreign patents Multiple indications: Prolanta has the potential to treat other gynecological cancers Oncolix
23 Clinical Development Plan for Ovarian Cancer Phase I Safety/Efficacy (First 3 Patients Completed) Monotherapy in 12 to 18 Platinum Resistant Subjects 99-day trial File for Accelerated Approval (Fast Track) (Breakthrough) Phase I Safety/Efficacy Combination with Platinum/Taxane in 20 Recurrent Patients 28-day trial Phase IIa Efficacy Trial Combination with Platinum/Taxane vs Chemo alone in Recurrent Patients 40 Patients (Combo) 40 Patients (Chemo Alone) 9-month trial Phase IIb Pivotal Trial (USA) Combination with Platinum/Taxane vs Chemo alone in Recurrent Patients 160 Patients (Combo) 80 Patients (Chemo Alone) 9 to 12 month trial Oncolix
24 Ovarian Cancer Clinical Trials Monotherapy & chemo combination strategy Phase I (monotherapy) [in progress] ipot (Initial Prolanta Ovarian Trial) Subjects, recurrent or persistent disease Safety, biomarker evaluation and efficacy trends Three escalating doses 99-day trial Phase I (combination with chemo) Prolanta+chemotherapy Safety, biomarkers and efficacy (PFS and OS) 20 Patients in dose escalation phase (28 days) Commences after Phase I monotherapy trial Phase IIa (combination with chemo) Prolanta+chemotherapy vs chemotherapy alone Safety, biomarkers and efficacy (PFS and OS) 40 Patients in each arm (9 months) Phase IIb Pivotal (combination with chemo) Prolanta+chemotherapy vs chemo alone Biomarkers and efficacy (PFS and OS) 240 Patients (160 Patients Combo and 80 Patients Chemo) 9 to 12 month trial Oncolix
25 Milestones and Capital Raised $3 MM GHS Jan 07 $3.5 MM GHS Jan 09 $1.5 MM BioVectra (PIK) Aug 09 $2.4 MM ETF Oct 2010 $2.4 MM $1.1MM ETF Bridge Oct Loan 2010 Mar 2012 $4.2+ MM Jan 2015 License or Sell Company Product Indication Research Mfg Optimization Pre-clinical Phase I Phase IIa Phase IIb Prolanta Ovarian Cancer N/A N/A Prolanta Ovarian/ Combo Therapy Prolanta Uterine Cancer Prolanta Breast Cancer To be pursued with a pharmaceutical partner or post-approval of ovarian indication Oncolix
26 Capital Requirements Expanded Clinical and Regulatory Involvement VP Clinical Operations (2018) Director of Clinical Operations, CRA (2017) Director of Project Management (2017) HIRED Expanded sponsored research at MD Anderson to uterine cancer Sponsored research at UC-SF for breast cancer Capital Requirements Through Phase 2b $29.8 million capital raise to fund ovarian cancer monotherapy through Phase IIb trial results (monotherapy)and combination with chemotherapy trials through Phase 2b $ 5.1 M $8.9M 15.8M Oncolix
27 Financing History Greenville Hospital System (GHS) $7.7 million BioVectra (PIK) $1.5 million Emerging Technology Fund $3.9 million Clinical Accelerator (10% PIK) $0.05 million PoC Capital/Integrium (PIK) $1.5 million Series B in progress $5.0 million (estimate) Institutional Investors Family Offices Accredited Investors Oncolix
28 Capitalization Percentage of Fully Diluted GHC Research and Development 47.0 CEO 4.9 Founding Scientists and Others 6.1 Contract Manufacturer and CRO 11.9 Texas Emerging Technology Fund % Oncolix
29 Prolanta Investment Highlights Unmet medical need provides opportunity for accelerated approval through well-defined regulatory pathway Novel Mechanisms of Action Autophagy (programmed cell death) that selectively targets gynecological cancer cells Inhibition of cell proliferation signaling (JAK/STAT5/RAS/Raf) Reduction of Glutathione-S-Transferase clearance of chemotherapy agents, enhancing platinum and taxane therapy Strong preclinical evidence of efficacy Synergistic or additive to current therapies Reliable manufacturing under an FDA-reviewed process with proven scalability Proprietary patent position Positioned to be used primarily as a combination with chemotherapy or as a monotherapy in those patients who have failed chemotherapy Oncolix
30 Supplemental Information
31 G129R Efficacy (Growth Inhibition) 3-D Cultured HeyA8 Spheroids Real-time video microscopy for visualizing growth inhibition by Prolanta (G129R) (A) Time-lapse photomicroscopy was used to study HeyA8 ovarian cancer cells cultured in the Matrigel embedded condition (spheroids). Cells were either treated with (1) control (2) prolactin (PRL), (3) Prolanta (G129R) or (4) combination of PRL+G129R. Representative photomicrographs taken during filming are shown in phase contrast; approximate time elapsed (minutes): (a) 240; (b) 600 and (c) 2800 minutes. (B) Quantitative measurement of spheroid structure formulated at 48 hours of treatments with (1) control (2) PRL, (3) G129R or (4) combination of PRL+G129R. * p<0.05; ** p<0.01. Oncolix
32 Prolactin Confers Resistance to Chemotherapy The efficacy of therapeutic doses of chemotherapy drugs (red box) was reduced by pretreatment with prolactin in MDA-MD-468 breast cancer cells. The mechanism of action was not determined. Chemotherapy Drug Dose (ng/ml) Pretreatment with prolactin (PRL, 25 ng/ml) for 24 hours followed by chemotherapy drug exposure for 4 days. Chemotherapy drug exposure for 4 days * Significant difference versus control (chemotherapy drug alone) LaPensee, et al. Carcinogenesis vol.30 no.8 Oncolix
Corporate Presentation June 2017
Corporate Presentation June 2017 Safe Harbor Certain of the statements and the projections set forth in this presentation constitute forward-looking statements. Forward-looking statements include, without
More informationCorporate Presentation. October 2017
AEPP Breakthrough technology for women s cancers Corporate Presentation October 2017 Oncolix 2017 1 Safe Harbor Certain of the statements and the projections set forth in this presentation constitute forward-looking
More informationCorporate Presentation. March 2018
OTCQB: ONCX Breakthrough technology for women s cancers Corporate Presentation March 2018 Oncolix 2018 1 Safe Harbor Certain of the statements and the projections set forth in this presentation constitute
More informationCorporate Presentation. July 2018
OTCQB: ONCX Breakthrough technology for women s cancers Corporate Presentation July 2018 Oncolix 2018 1 Safe Harbor Certain of the statements and the projections set forth in this presentation constitute
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Rodman & Renshaw 19 th Annual Global Investment Conference Michael R. Garone, Principal Executive Officer and CFO Forward-Looking
More informationIMMUNOMEDICS, INC. November Advanced Antibody-Based Therapeutics. Oncology Autoimmune Diseases
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases November 2017 Forward-Looking Statements This presentation, in addition to historical information, contains certain
More informationCorporate Presentation
Corporate Presentation Leerink Global Healthcare Conference February 14 th -15 th, 2018 C O N F I D E N T I A L a n d P R O P R I E T A R Y Forward Looking Statements / Safe Harbor This presentation contains
More informationPierre Legault CEO June 2, 2014
April 2012 Pierre Legault CEO June 2, 2014 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking
More informationAvenue Therapeutics, Inc. August 2016
Avenue Therapeutics, Inc. August 2016 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning of the safe
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer September 2013 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results
More informationAvenue Therapeutics, Inc. September 2016
Avenue Therapeutics, Inc. September 2016 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning of the
More informationNovogen Limited. An emerging oncology drug developer with two clinical-stage programs NRT NVGN. April 2017
Novogen Limited An emerging oncology drug developer with two clinical-stage programs NRT April 2017 NVGN Forward-Looking Statements This presentation contains forward-looking statements within the meaning
More informationClovis Oncology Announces Q Operating Results and Corporate Update. November 3, :05 PM ET
Clovis Oncology Announces Q3 2016 Operating Results and Corporate Update November 3, 2016 4:05 PM ET Rucaparib New Drug Application (NDA) accepted for Priority Review in the treatment of advanced BRCA-mutant
More informationBusiness Update & Financial Results for Q1 2018
Business Update & Financial Results for Q1 2018 May 15, 2018 Disclaimer The statements made in this presentation may include forward-looking statements regarding the future operations of ERYTECH Pharma
More informationAvenue Therapeutics, Inc. May 2017
Avenue Therapeutics, Inc. May 2017 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning of the safe
More informationVAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients. September 2018
VAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients September 2018 Forward-Looking Statements Any statements contained in this presentation that do not describe historical facts may
More informationNew Generation of T-cell Therapeutics
New Generation of T-cell Therapeutics Corporate Overview January 2017 NASDAQ: TPIV 1 Safe Harbor Statement Certain statements contained herein are forward-looking statements within the meaning of the safe
More informationBobby W. Sandage, Jr., PhD President & Chief Executive Officer. Lazard Capital Markets 8 th Annual Healthcare Conference
Bobby W. Sandage, Jr., PhD President & Chief Executive Officer Lazard Capital Markets 8 th Annual Healthcare Conference Statements in this presentation that are not descriptions of historical facts are
More informationInvestor Call. May 19, Nasdaq: IMGN
Investor Call May 19, 2017 Nasdaq: IMGN Forward-Looking Statements This presentation includes forward-looking statements based on management's current expectations. These statements include, but are not
More informationFor personal use only
Targeted DEP shows sustained superior performance in ovarian cancer model Melbourne, Australia; 2 February 2016: Starpharma (ASX: SPL, OTCQX: SPHRY) today announced the final results of the preclinical
More informationNEWS RELEASE Media Contact: Megan Pace Investor Contact: Kathee Littrell Patient Inquiries: Ajanta Horan
NEWS RELEASE Media Contact: Megan Pace 650-467-7334 Investor Contact: Kathee Littrell 650-225-1034 Patient Inquiries: Ajanta Horan 650-467-1741 GENENTECH RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR
More informationGenta Incorporated. A Multiproduct Late-Stage Oncology Company
Genta Incorporated A Multiproduct Late-Stage Oncology Company This presentation may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking
More informationCompany presentation. Claudio Bordignon, Chairman and CEO. Jefferies Global Healthcare Conference New York, 7 June 2012
Company presentation Claudio Bordignon, Chairman and CEO Jefferies Global Healthcare Conference New York, 7 June 2012 Forward-looking statements The presentation contains certain forward-looking statements.
More informationInvestor Presentation
Investor Presentation June 2017 Joe Turgeon President and Chief Operating Officer Safe Harbor Statement This presentation contains forward-looking statements regarding future events and the future performance
More informationCorporate Overview. February 2018 NASDAQ: CYTR
Corporate Overview February 2018 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER
More informationForward-Looking Statements
Investor Presentation May 2012 Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended.
More information[ NASDAQ: MEIP ] Cowen and Company Health Care Conference March 2015
[ NASDAQ: MEIP ] Cowen and Company Health Care Conference March 2015 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events or
More informationClovis Oncology Announces First Quarter 2017 Operating Results. May 3, :06 PM ET
Clovis Oncology Announces First Quarter 2017 Operating Results May 3, 2017 4:06 PM ET Strong Q1 launch quarter for Rubraca (rucaparib) in U.S. with $7M reported in net sales Clovis notified that ARIEL3
More informationNEWS RELEASE Media Contact: Krysta Pellegrino (650) Investor Contact: Sue Morris (650) Advocacy Contact: Kristin Reed (650)
NEWS RELEASE Media Contact: Krysta Pellegrino (650) 225-8226 Investor Contact: Sue Morris (650) 225-6523 Advocacy Contact: Kristin Reed (650) 467-9831 FDA APPROVES AVASTIN IN COMBINATION WITH CHEMOTHERAPY
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C Form 6-K
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month
More informationLION. Corporate Presentation June 2016 BIOTECHNOLOGIES. Leadership & Innovation in Oncology
LION BIOTECHNOLOGIES Leadership & Innovation in Oncology Corporate Presentation June 2016 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More informationFor personal use only
ASX:NRT NASDAQ:NVGN Novogen Ltd (Company) MARKET RELEASE 12 September 2016 NOVOGEN PRESENTS AT RODMAN & RENSHAW CONFERENCE ABN 37 063 259 754 Capital Structure Ordinary Shares on issue: 429 M Board of
More informationThird Quarter 2015 Earnings Call. November 9, 2015
Third Quarter 2015 Earnings Call November 9, 2015 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements
More informationFull Year 2017 Financial Results. February 14, 2018
Full Year 2017 Financial Results February 14, 2018 Agios Conference Call Participants Prepared Remarks Introduction KENDRA ADAMS, Sr. Director, Investor Relations 2018 Vision & Key Milestones DAVID SCHENKEIN,
More informationA company developing innovative, high-impact drugs for cancer
A company developing innovative, high-impact drugs for cancer Investor Briefing March 2019 ASX: KZA NASDAQ : KZIA Twitter: @KaziaTx Forward-Looking Statements This presentation contains forward-looking
More informationFor personal use only. A new company with: a new technology platform for cancer drug development a new management team a new Board
A new company with: a new technology platform for cancer drug development a new management team a new Board Disclaimer This presentation is confidential and is not an offer or a recommendation or intended
More informationObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update
ObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update IMPLANT 4 trial of nolasiban in IVF starting in Q4 2018, European MAA filing expected late 2019 24-week data from Phase
More informationPhoenix Molecular Designs
Phoenix Molecular Designs DESIGNING PRECISE THERAPEUTICS TO REVOLUTIONIZE TREATMENT Our Team Dr. Sandra Dunn, Ph.D. Dr. Anna Stratford, Ph.D. Dr. Aarthi Jayanthan, Ph.D. Dr. Zaihui Zhang CEO, CSO UBC Professor
More informationPfizer Presents Final Phase 2 Data on Investigational PARP Inhibitor Talazoparib in Patients with Germline BRCA-Positive Advanced Breast Cancer
For immediate release June 3, 2017 Media Contact: Sally Beatty (212) 733-6566 Investor Contact: Ryan Crowe (212) 733-8160 Pfizer Presents Final Phase 2 Data on Investigational PARP Inhibitor Talazoparib
More information33 rd Annual J.P. Morgan Healthcare Conference. January 2015
33 rd Annual J.P. Morgan Healthcare Conference January 2015 Forward-looking Statements This presentation contains forward-looking statements, which express the current beliefs and expectations of management.
More informationFor personal use only
Cancer killing viruses Oncolytic Virotherapeutics Bryan Dulhunty Managing Director Bell Potter Life Sciences Conference Building a Global Profile May 2102 bryan.dulhunty@viralytics.com www.viralytics.com
More informationDARA Reports Year-End 2012 Financial Results
April 1, 2013 DARA Reports Year-End 2012 Financial Results Company Provides a Commercial Portfolio and Development Pipeline Business Update RALEIGH, NC -- (MARKETWIRE) -- 04/01/13 -- DARA BioSciences,
More informationFor personal use only. General Meeting 6 March 2014
General Meeting 6 March 2014 Disclaimer Certain statements made in this presentation are forward looking statements within the meaning of the safe harbour provisions of the United States Private Securities
More informationDendrimer-Oxaliplatin shows better anti-cancer efficacy and less toxicity
Dendrimer-Oxaliplatin shows better anti-cancer efficacy and less toxicity Melbourne, Australia; Wednesday 11 September 2013: Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced it had achieved
More informationValneva Reports Strong 2017 Revenues Driven by Double Digit Product Sales Growth
Valneva Reports Strong 2017 Revenues Driven by Double Digit Product Sales Growth Strong sales performance in 2017 (unaudited) Total revenues of 109.8 million in 2017 (2016-97.9 million) representing year-on-year
More informationInducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy
Inducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy Company Overview, September 2018 Safe Harbor Statement This presentation contains forward-looking
More informationMedia Contact: Ron Rogers Investor Contact: Scott Gleason (801) (801)
News Release Media Contact: Ron Rogers Investor Contact: Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Receives FDA Approval of BRACAnalysis CDx as Companion
More informationCAELUM BIOSCIENCES. Corporate Overview May, 2017
CAELUM BIOSCIENCES Corporate Overview May, 2017 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning
More information37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE
37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE January 2019 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationCytoDyn Announces Initiation of Metastatic Triple Negative Breast Cancer Trial and Reiterates Phase 3 Goal in Cancer
November 26, 2018 CytoDyn Announces Initiation of Metastatic Triple Negative Breast Cancer Trial and Reiterates Phase 3 Goal in Cancer VANCOUVER, Washington, Nov. 26, 2018 (GLOBE NEWSWIRE) -- CytoDyn Inc.
More informationDicerna Pharmaceuticals Overview. Delivering RNAi-Based Breakthrough Therapies
Pharmaceuticals Overview Delivering RNAi-Based Breakthrough Therapies Forward-Looking Statements This information may contain projections and other forward looking statements regarding future events, including
More information[ NASDAQ: MEIP ] August 2014
[ NASDAQ: MEIP ] August 2014 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events or results may differ materially from those
More informationOragenics Shareholder Update
January 4, 2017 Oragenics Shareholder Update Advances Drug Development Programs Focused on Conditions with Significant Unmet Medical Needs TAMPA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (NYSE MKT:OGEN.BC),
More informationINTERIM MANAGEMENT STATEMENT Q3 2017
INTERIM MANAGEMENT STATEMENT Q3 2017 Significant progress across all clinical programs New pre-clinical immunooncology data to be presented during R&D Day in New York Research & Development highlights:
More informationOncoSec Provides 2018 Business Outlook
January 3, 2018 OncoSec Provides 2018 Business Outlook Complete stage 1 enrollment of PISCES/KEYNOTE-695 clinical trial of ImmunoPulse IL-12 in combination with KEYTRUDA (pembrolizumab) Present preliminary
More informationHALOZYME REPORTS SECOND QUARTER 2018 RESULTS
Contacts: Robert H. Uhl Managing Director Westwicke Partners, LLC 858-356-5932 robert.uhl@westwicke.com Laurie Stelzer 858-704-8222 ir@halozyme.com FOR IMMEDIATE RELEASE HALOZYME REPORTS SECOND QUARTER
More informationDetermined to realize a future in which people with cancer live longer and better than ever before 4Q18 EARNINGS PRESENTATION MARCH 2019
Determined to realize a future in which people with cancer live longer and better than ever before 4Q18 EARNINGS PRESENTATION MARCH 2019 Forward-looking statements disclosure This presentation contains
More informationCorporate Overview. May 2017 NASDAQ: CYTR
Corporate Overview May 2017 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER MATERIALLY
More informationRespireRx Pharmaceuticals Inc. Executives Presenting at the International Cannabinoid Derived Pharmaceuticals Summit
RespireRx Pharmaceuticals Inc. Executives Presenting at the International Cannabinoid Derived Pharmaceuticals Summit December 11 12, 2018 Workshops, December 10, 2018 The Revere Hotel 200 Stuart St., Boston,
More informationDS-8201 Strategic Collaboration
DS-8201 Strategic Collaboration DAIICHI SANKYO CO., LTD George Nakayama Chairman and CEO March 29, 2019 Forward-Looking Statements Management strategies and plans, financial forecasts, future projections
More informationMerrimack Pharmaceuticals: A Refocused R&D Company January 2017
Merrimack Pharmaceuticals: A Refocused R&D Company January 2017 Forward Looking Statements This presentation contains forward-looking statements of the Company that involve substantial risks and uncertainties.
More informationInnovative Nuclear Receptor Modulation Medicine
Innovative Nuclear Receptor Modulation Medicine Dale C Leitman, M.D., Ph.D. Isaac Cohen, O.M.D., Ph.D. October 2015 Corporate Mission Iaterion, Inc. is Developing Novel Pharmaceutical Nuclear Receptor
More informationSpectrum Pharmaceuticals
Spectrum Pharmaceuticals Joe Turgeon President and CEO June 2018 Investor Presentation 1 Safe Harbor Statement This presentation contains forward looking statements regarding future events and the future
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer March 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward-looking statements. Rexahn's actual results may
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer January 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results
More informationInvestor Presentation June 2012 NASDAQ: CEMI
Investor Presentation June 2012 NASDAQ: CEMI Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act
More information34 th Annual J.P. Morgan Healthcare Conference
JANUARY 2016 34 th Annual J.P. Morgan Healthcare Conference [ 1 ] Forward Looking Statements SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS In addition to historical information, this presentation contains
More informationMedifocus, Inc. OTCQX: MDFZF TSXV: MFS.
Medifocus, Inc. OTCQX: MDFZF TSXV: MFS www.medifocusinc.com Except for historical information, the statements made in this presentation are forward-looking statements involving significant risks and uncertainties.
More informationDawson James Conference
Dawson James Conference October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations regarding
More informationAerpio Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update
Aerpio Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update TIME-2b Clinical Trial of AKB-9778 in Patients with Diabetic Retinopathy Remains on Track Conference Call
More informationNewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results
July 31, 2015 NewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results -Management to Host Conference Call Today at 8:30 a.m. ET- AMES, Iowa, July 31,
More informationSunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results
Investor and Media Inquiries: David Pitts Argot Partners 212-600-1902 Eric Bjerkholt Sunesis Pharmaceuticals Inc. 650-266-3717 Sunesis Pharmaceuticals Reports Second Quarter 2011 Financial Results SOUTH
More informationAVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC
FOR IMMEDIATE RELEASE AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC - Tivozanib is the First Agent to Demonstrate Greater than One Year
More informationVeriStrat Poor Patients Show Encouraging Overall Survival and Progression Free Survival Signal; Confirmatory Phase 2 Study Planned by Year-End
AVEO and Biodesix Announce Exploratory Analysis of VeriStrat-Selected Patients with Non-Small Cell Lung Cancer in Phase 2 Study of Ficlatuzumab Presented at ESMO 2014 Congress VeriStrat Poor Patients Show
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 3Q 2018 EARNINGS PRESENTATION NOVEMBER 2018 1 Forward-looking statements disclosure This presentation
More informationAmicus Establishes Gene Therapy Pipeline for Lysosomal Storage Disorders (LSDs) Conference Call and Webcast September 20, 2018
Amicus Establishes Gene Therapy Pipeline for Lysosomal Storage Disorders (LSDs) Conference Call and Webcast September 20, 2018 Introduction 2 Safe Harbor This presentation contains "forward-looking statements"
More informationPRESENTATION. AGM 27 th OCTOBER 2015 ASX: PAA ACN
PRESENTATION AGM 27 th OCTOBER 2015 ASX: PAA ACN 094 006 023 Disclaimer This presentation does not constitute investment advice. Neither this presentation nor the information contained in it constitutes
More informationHalaven TM FDA Approval Press Conference Statement
Halaven TM FDA Approval Press Conference Statement Haruo Naito President Eisai Co., Ltd. at Tokyo Headquarters Auditorium November 16, 2010 It is with great pleasure that I inform you all here today that
More informationwww. isotopeworld.com Advanced Medical Isotope Corporation
www. isotopeworld.com Advanced Medical Isotope Corporation www. isotopeworld.com James C. Katzaroff Founder, CEO, Chairman December 5, 2016 Safe Harbor Statement This Overview contains forward-looking
More informationE N H A N C IN G HE A LTH THRO U GH CANNABIS S CIENCE
I N V E S T O R P R E S E N TAT I O N Q 4 2 0 1 6 TM HEALTH THERAPEUTICS E N H A N C IN G HE A LTH THRO U GH CANNABIS S CIENCE T S X. V: E M H DISCLAIMER THE STATEMENTS MADE IN THIS PRESENTATION MAY INCLUDE
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer June 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results may
More informationRexahn Pharmaceuticals Overview
Rexahn Pharmaceuticals Overview May 2018 Safe Harbor Statement The statements that follow (including projections and business trends) are forward-looking statements. Rexahn s actual results may differ
More informationCORPORATE PRESENTATION
CORPORATE PRESENTATION June 2017 FORWARD LOOKING SAFE HARBOR STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationInovio Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter)
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event
More informationInvestor presentation. Bioshares Biotech Summit July 2017
Investor presentation Bioshares Biotech Summit 2017 22 July 2017 1 Disclaimer Some of the information in this presentation may refer to Dimerix Limited ( Dimerix or the Company ) based on information available
More informationDetermined to realize a future in which people with cancer live longer and better than ever before Q Conference Call
Reimagining Cancer Treatment Determined to realize a future in which people with cancer live longer and better than ever before Q1 2016 Conference Call 1 Forward-Looking Statements Disclosure This presentation
More informationCorporate Overview. July 2016 NASDAQ: CYTR
Corporate Overview July 2016 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES ASSOCIATED WITH A DEVELOPMENT-STAGE
More informationTargeting and Treating Cancer
Targeting and Treating Cancer Mark R. Baker, Chief Executive Officer Jefferies Healthcare Conference June 2015 Disclosure Notice This presentation may contain projections and other forward-looking statements
More informationTwo-stage study designed to evaluate tolerability and efficacy of pracinostat combined with azacitidine in patients with high and very high risk MDS
Helsinn Group and MEI Pharma Announce First Patient Dosed in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in Myelodysplastic Syndrome Two-stage study designed to evaluate tolerability
More informationSpecial Meeting in Lieu of Annual Meeting of Shareholders
Special Meeting in Lieu of Annual Meeting of Shareholders Thursday, June 19, 2008 James A. Bianco, M.D. President and CEO Agenda Call meeting to order Introduction of the inspector of elections, secretary,
More informationADAPTIMMUNE INVESTOR PRESENTATION. August 2016
ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
More informationNASDAQ: CYTR FIGHTING CANCER WITH CUTTING EDGE SCIENCE. Corporate Overview. July 2018
NASDAQ: CYTR Corporate Overview July 2018 CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER MATERIALLY
More informationCombining HS-110 and anti-pd-1 in NSCLC. September 1, 2015
Combining HS-110 and anti-pd-1 in NSCLC September 1, 2015 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking
More information3Q 2016 presentation
Arming the patient s immune system to fight cancer 3Q 2016 presentation 17 November 2016 Important notice and disclaimer This report contains certain forward-looking statements based on uncertainty, since
More informationCorporate Overview May 8, 2014
0 Corporate Overview May 8, 2014 NASDAQ: CRIS Forward Looking Statements This presentation contains statements about Curis future expectations, plans and prospects that constitute forward-looking statements
More informationOWC PHARMACEUTICALS RESEARCH OTCQB:OWCP
OWC PHARMACEUTICALS RESEARCH OTCQB:OWCP Disclaimer This document details business information of OWC Pharmaceuticals Research Corp and/or our wholly-owned Israeli subsidiary, One World Cannabis Ltd. (collectively,
More informationBioCryst Pharmaceuticals
BioCryst Pharmaceuticals Jefferies 2010 Global Life Sciences Conference New York Stuart Grant Senior Vice President & Chief Financial Officer Rob Bennett Executive Director, Investor Relations & Business
More informationFor personal use only
Australian Securities Exchange Limited Companies Announcements Office SYDNEY 4 April, 2012 New Australian Drug Developer Lists on ASX Key points Growth-focused Australian drug and therapeutic development
More informationDelMar Pharmaceuticals Inc. (OTCQX: DMPI, Target Price: $5.75)
Equity Healthcare / Biotechnology Update (December 3, 2015) DelMar Pharmaceuticals Inc. (OTCQX: DMPI, Target Price: $5.75) DelMar Pharmaceuticals, Inc. ( DelMar, OTCQX: DMPI) is a clinical stage biotechnology
More information[ NASDAQ: MSHL ] Southern California Investor Conference August 29, 2011
[ NASDAQ: MSHL ] Southern California Investor Conference August 29, 2011 Forward-Looking Statements These slides and the accompanying oral presentation contain forward-looking statements. Actual events
More information